TABLE 1.
Overview of the antibody-drug conjugates approved for breast (triple-negative and HER2-positive) and urothelial carcinomas. ADCs approved for other indications are not listed
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.